市场调查报告书
商品编码
1426944
MRI 造影剂市场- 副产品(细胞外製剂{离子、非离子}、肝胆製剂)、类型(品牌、仿製药)、应用(神经、肌肉骨骼、心血管、癌症)、最终用途-全球预测,2024- 2032 年MRI Contrast Media Market - By Product (Extracellular Agents {Ionic, Non-ionic}, Hepatobiliary Agents), Type (Branded, Generics), Application (Neurological, Musculoskeletal, Cardiovascular, Cancer), End-use- Global Forecast, 2024-2032 |
由于医疗保健系统对先进影像技术的严重依赖,预计 2024 年至 2032 年全球 MRI 造影剂市场将以 4.6% 的CAGR成长。
根据世界卫生组织 2023 年的报告,非传染性疾病 (NCD) 占全球死亡人数的 74%,每年夺走 4,100 万人的生命。其中,1,700万人在70岁前死于非传染性疾病,其中86%的过早死亡发生在低收入和中等收入国家。全球与生活方式相关的疾病(例如糖尿病和肥胖症)的增加导致需要诊断成像的疾病的发生率更高。 MRI 造影剂在检测和监测这些疾病方面发挥着至关重要的作用,提供对内臟器官进展和影响的非侵入性见解。此外,增加对医疗基础设施的投资,特别是在新兴经济体,正在为采用最先进的医疗设施创造有利的环境。
全球 MRI 造影剂产业根据产品、类型、应用和地区进行分类。
由于其在 MRI 扫描过程中增强血管和心血管结构可视性的作用,血池剂领域预计将在 2032 年获得牵引力。随着新型配方的引入,显着的进步提高了成像品质并减少了副作用,有利于血池剂的采用。这使得特定器官或组织的精确成像成为可能,从而提高了诊断准确性。
仿製药市场预计将在研究期间强劲成长,因为它为医疗保健提供者和患者提供了具有成本效益的替代方案。仿製药的成本效益和可比较的功效正在推动它们的采用,特别是在医疗保健预算受到严格审查的地区。此外,持续的产品创新预计将推动产业成长。
在慢性病盛行率不断上升以及医疗基础设施投资不断增加的推动下,亚太地区 MRI 造影剂市场预计在 2024 年至 2032 年期间持续成长。中国和印度等国家正在经历快速的城市化和不断增长的中产阶级人口,导致医疗保健支出增加。此外,支持性的监管框架和持续的研发努力正在促进先进医学影像技术在该地区的采用。
The global MRI contrast media market is expected to grow at a CAGR of 4.6% during 2024-2032, driven by the heavy reliance of healthcare systems on advanced imaging technologies.
According to a report by WHO in 2023, noncommunicable diseases (NCDs) account for 74% of global deaths, claiming 41 million lives annually. Of these, 17 million people die from NCDs before the age of 70, with 86% of premature deaths occurring in low- and middle-income countries. The global increase in lifestyle-related diseases, such as diabetes and obesity, contributes to a higher incidence of conditions that necessitate diagnostic imaging. MRI contrast media plays a vital role in detecting and monitoring these diseases, offering non-invasive insights into the progression and impact on internal organs. Moreover, increasing investments in healthcare infrastructure, particularly in emerging economies, are creating a conducive environment for the adoption of state-of-the art medical facilities.
The global MRI contrast media industry is classified based on product, type, application, and region.
The blood-pool agent segment is set to gain traction through 2032, driven by its role in enhancing the visibility of blood vessels and cardiovascular structures during MRI scans. The significant advancements, with the introduction of novel formulations that offer improved imaging quality and reduced side effects are favoring adoption of blood-pool agent. This has enabled the precise imaging of specific organs or tissues, thereby enhancing diagnostic accuracy.
The generics segment is anticipated to grow robustly during the study period as it provides cost-effective alternative to healthcare providers and patients. The cost-effectiveness and comparable efficacy of generic products are driving their adoption, especially in regions where healthcare budgets are under scrutiny. Moreover, continuous product innovation is expected to propel industry growth.
Asia Pacific MRI contrast media market is poised to grow continuously during 2024-2032, driven by the increasing prevalence of chronic diseases, coupled with rising healthcare infrastructure investments. Countries such as China and India are witnessing rapid urbanization and a growing middle-class population, contributing to increased healthcare spending. Additionally, supportive regulatory frameworks and constant R&D efforts are fostering the adoption of advanced medical imaging technologies in the region.